Product Information
BUPRENORPHINE 20 MCG/HR PATCH is a generic product labeled by Teva Pharmaceuticals USA Inc., priced at $58.8288 per EA under NDC 00093365940. Its NADAC has been published 344 times since Dec 12, 2018.
FDA first approved this application on Nov 20, 2018. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
Strength
20 ug/h
Manufacturer
Teva Pharmaceuticals USA Inc.NDC
00093365940
Classification
Generic
Dosage Form
PATCH, EXTENDED RELEASE
Route
TRANSDERMAL
Effective Date
9/23/2026
Active Ingredients
BUPRENORPHINEApproval Type
Generic (ANDA)
FDA Application
ANDA204937FDA Approved
11/20/2018
TE Code
AB
On Market Since
11/26/2018
Pharmacological Classes
Price Statistics
The NADAC for BUPRENORPHINE 20 MCG/HR PATCH has been published 344 times since Dec 12, 2018, and over the history we have for it it has declined 56.6%. The table below summarizes its recorded NADAC range and movement.
| Current price | $58.8288 per EA |
|---|---|
| All-time high | $137.4668 (Feb 10, 2021) |
| All-time low | $42.3325 (Jul 17, 2024) |
| 52-week high | $58.8288 |
| 52-week low | $52.6588 |
| Median price | $81.9169 |
| Average price | $87.2291 |
| Largest weekly change | +51.6% (Aug 21, 2024) |
| Weeks tracked | 344 |
| Tracking since | Dec 12, 2018 |
Generic Alternatives
The matcher finds 3 manufacturers offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). None of the shown alternatives sit below the current price. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Teva Pharmaceuticals USA Inc. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
Buprenorphine market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Partial Opioid Agonist class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of BUPRENORPHINE 20 MCG/HR PATCH?
The current National Average Drug Acquisition Cost (NADAC) for BUPRENORPHINE 20 MCG/HR PATCH, manufactured by Teva Pharmaceuticals USA Inc., is $58.8288 per EA (NDC 00093365940), effective Sep 30, 2026.
How has the price of BUPRENORPHINE 20 MCG/HR PATCH changed over time?
Over the history we have for it, the NADAC for BUPRENORPHINE 20 MCG/HR PATCH has declined 56.6%. It has been tracked across 344 weekly CMS publications since Dec 12, 2018.
What are the highest and lowest recorded NADAC prices for BUPRENORPHINE 20 MCG/HR PATCH?
Since Dec 12, 2018, the NADAC for BUPRENORPHINE 20 MCG/HR PATCH has ranged from a low of $42.3325 (Jul 17, 2024) to a high of $137.4668 (Feb 10, 2021), with a median of $81.9169 per EA.
Are there cheaper alternatives to BUPRENORPHINE 20 MCG/HR PATCH?
3 manufacturers publish a NADAC-priced product with the same active ingredient and strength as BUPRENORPHINE 20 MCG/HR PATCH in a comparable dosage form, but none are currently priced below it.
Who manufactures BUPRENORPHINE 20 MCG/HR PATCH?
BUPRENORPHINE 20 MCG/HR PATCH (NDC 00093365940) is labeled by Teva Pharmaceuticals USA Inc., and CMS classifies it as a generic product.